List of Excipients in Branded Drug BUTRANS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Knoa Pharma LLC	BUTRANS	buprenorphine	59011-751	ETHYL LEVULINATE
Knoa Pharma LLC	BUTRANS	buprenorphine	59011-751	OLEYL OLEATE
Knoa Pharma LLC	BUTRANS	buprenorphine	59011-751	POVIDONE

Butrans Excipient Strategy and Commercial Opportunities in Buprenorphine Transdermal Patches

Last updated: September 15, 2026

Butrans is a buprenorphine transdermal system that uses an adhesive matrix to deliver buprenorphine through the skin over seven days. Its commercial value is tied to patch adhesion, controlled drug release, skin tolerability, dose consistency, and protection from heat-related dose dumping. The strongest excipient opportunities are in pressure-sensitive adhesive systems, crystallization control, permeation optimization, and skin-contact performance.

The principal market opportunities are generic buprenorphine patches, lifecycle-improved systems, regional products, and excipient platforms that can be reused across low-dose transdermal drugs.

What excipients are used in Butrans patches?

Butrans uses a drug-in-adhesive transdermal design. The active ingredient is buprenorphine, a Schedule III opioid agonist-antagonist. The FDA labeling identifies levulinic acid, oleic acid, povidone, and polyisobutylene among the inactive ingredients in the drug matrix. The patch also contains a backing layer and a removable release liner made from polymeric materials.[1]

Component	Reported or functional material	Commercial function
Active pharmaceutical ingredient	Buprenorphine	Analgesic drug
Permeation enhancer	Oleic acid	Increases skin permeation by modifying lipid domains in the stratum corneum
Acidic modifier	Levulinic acid	Supports drug solubilization and matrix performance
Polymer or solubilizer	Povidone	Helps maintain drug distribution and matrix uniformity
Pressure-sensitive adhesive	Polyisobutylene-based adhesive	Provides skin contact and controls drug release
Backing layer	Polyester or related polymer film	Protects the matrix and limits drug loss
Release liner	Silicone-treated polymer film	Protects the adhesive before application

The exact commercial formulation, polymer grade, molecular-weight distribution, coating weight, and manufacturing process are critical. Two patches can list similar excipients while producing different release rates, adhesion profiles, or skin-irritation outcomes.

How does Butrans use excipients to control drug delivery?

The Butrans matrix has to perform several functions at the same time. It must dissolve or disperse a low-dose opioid, remain physically stable during storage, adhere for seven days, release drug at a controlled rate, and avoid excessive skin irritation.

Skin permeation

Buprenorphine has high potency, making transdermal delivery commercially practical at relatively low mass loading. Oleic acid is a logical permeation enhancer because it interacts with skin lipids and can increase drug diffusivity. The concentration must be controlled closely. Excessive enhancer loading can increase erythema, sensitization risk, crystallization, or adhesive failure.

A commercial developer can pursue:

• Alternative fatty-acid enhancers
• Fatty alcohol or ester systems
• Terpene-based enhancers
• Combinations of enhancer and co-solvent
• Lower-irritation enhancer systems
• Microstructured or crystallization-resistant matrices

The opportunity is to improve flux without increasing total buprenorphine loading. Higher loading can create stability and abuse-deterrence issues.

Drug solubilization and crystallization control

A transdermal matrix must maintain buprenorphine in a stable molecularly dispersed or finely dispersed state. Drug crystallization can reduce the available drug concentration, change release kinetics, and create dose-uniformity failures.

Povidone can help with drug distribution and matrix consistency. Levulinic acid and oleic acid can modify the drug’s solubility environment. Commercial development should evaluate:

• Povidone grade and molecular weight
• Drug-to-polymer ratio
• Residual solvent levels
• Water activity
• Crystallization after accelerated aging
• Drug distribution across the coated web
• Edge-to-center content uniformity
• Changes after heat exposure

A formulation with initially acceptable release may fail after storage if buprenorphine migrates, crystallizes, or partitions into the backing layer.

Adhesion over seven days

Seven-day adhesion is a defining product attribute. Polyisobutylene-based adhesives are useful because they offer chemical stability, low volatility, and long-duration skin contact. Performance depends on polymer molecular weight, tackifier content, coating thickness, and the balance between tack, peel strength, and shear resistance.

The main engineering targets are:

Performance issue	Excipient or design response
Patch edge lift	Increase tack or modify adhesive rheology
Complete detachment	Improve peel adhesion and skin wetting
Residue on skin	Reduce low-molecular-weight adhesive fractions
Skin stripping	Lower peel force and optimize adhesive modulus
Poor adhesion in sweat	Improve hydrophobicity and cohesive strength
Drug migration into adhesive	Adjust polymer polarity and drug solubility
Cold-flow during storage	Increase cohesive strength or modify backing support

Generic developers must match the reference product’s clinically relevant adhesion behavior, not only its in vitro drug-release profile.

What formulation patents protect Butrans-type systems?

Butrans protection has historically involved the drug product, transdermal delivery system, manufacturing process, and associated use claims. The relevant intellectual-property categories include:

1. Buprenorphine transdermal compositions
2. Drug-in-adhesive matrix systems
3. Permeation-enhancer combinations
4. Seven-day delivery systems
5. Patch construction and multilayer assemblies
6. Manufacturing and coating processes
7. Treatment of chronic pain with transdermal buprenorphine

Public patent records associated with Purdue and related entities include transdermal buprenorphine patents and continuation filings covering composition and delivery-system features. The commercially relevant patent question is whether a generic product would infringe a live claim directed to the specific adhesive matrix, enhancer combination, concentration range, or manufacturing process. The expiration analysis must be performed against current USPTO and FDA Orange Book records because patent status can change through disclaimers, terminal disclaimers, pediatric extensions, reexamination, or litigation outcomes.[2][3]

Why excipient claims can be commercially important

An excipient claim can create a stronger barrier than a narrow claim to the active ingredient. Buprenorphine itself is long-established and cannot support broad composition-of-matter exclusivity for Butrans. A patent covering a particular adhesive and enhancer combination may still affect a generic if the ANDA formulation relies on the same combination.

The strongest claims typically include:

• Defined ranges for permeation enhancers
• Polymer molecular-weight ranges
• Specific drug-to-adhesive ratios
• Crystallization-resistant compositions
• Adhesion performance linked to composition
• Seven-day release profiles
• Low-irritation systems
• Multilayer structures that limit drug loss

A formulation patent is less valuable if a generic can achieve equivalent delivery with a different adhesive, enhancer, or backing layer.

When does Butrans lose exclusivity?

Butrans received FDA approval in 2010 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.[1] FDA approval was supported by regulatory exclusivity, patents, and controlled-substance compliance requirements.

Exclusivity element	Butrans relevance
New drug approval	Established in 2010
Active ingredient	Buprenorphine was previously known
Product exclusivity	The principal protection comes from product-specific patents and regulatory exclusivity
Pediatric exclusivity	Must be confirmed in FDA records for the specific product
Orange Book patents	Relevant listed patents must be reviewed by expiration and claim scope
Generic pathway	ANDA applicants may use Paragraph IV certifications against listed patents
Controlled substance	Schedule III requirements apply to manufacturing, distribution, storage, and diversion controls

The loss of exclusivity is therefore not a single date. A generic can enter after applicable patents expire, are invalidated, are not infringed, or are resolved through a settlement. Regulatory exclusivity and patent exclusivity must be analyzed separately.

What Paragraph IV challenges and generic entry risks affect Butrans?

A generic sponsor seeking approval through an ANDA may submit a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. The filing can trigger patent litigation under the Hatch-Waxman framework and may create a 30-month FDA approval stay, subject to statutory exceptions and court developments.[4]

Generic entry risk is highest when:

• Listed patents cover limited formulation features
• The generic can design around the adhesive system
• The reference product has limited remaining market exclusivity
• Multiple manufacturers have filed ANDAs
• The product has no meaningful device or delivery-system barrier
• The market has established transdermal manufacturing capacity

Generic entry risk is lower when the reference product depends on difficult-to-reproduce adhesion performance, a narrow enhancer range, complex web-coating controls, or manufacturing know-how that is not fully disclosed in the public label.

For Butrans, the active ingredient presents little technical entry risk. The more important barriers are matrix uniformity, seven-day adhesion, skin tolerability, controlled release, and regulatory demonstration of equivalence.

What FDA regulatory requirements apply to generic Butrans patches?

A generic buprenorphine transdermal system must establish pharmaceutical equivalence and bioequivalence under the applicable FDA standards. Transdermal products require more than a conventional oral-tablet comparison.

Regulatory development generally includes:

• Same active ingredient and dosage form
• Same route of administration
• Matching strengths
• Comparative in vitro release
• Adhesion performance
• Skin irritation and sensitization evaluation
• Pharmacokinetic bioequivalence
• Drug-content uniformity
• Stability under long-term and accelerated conditions
• Extractables and leachables assessment
• Container-closure and pouch performance
• Manufacturing controls for coating and drying

A developer that changes the adhesive, permeation enhancer, or patch construction may need additional evidence. A major formulation change can create clinical or regulatory risk even when the nominal dose and delivery rate remain the same.

FDA guidance for transdermal and topical delivery systems places practical importance on adhesion, product quality, and comparative performance. Adhesion failures can affect both efficacy and safety because they may reduce delivery or lead patients to replace the patch early.[5]

What commercial opportunities exist for Butrans excipients?

Generic transdermal systems

The clearest opportunity is a lower-cost generic patch. Generic manufacturers can compete through:

• Lower-cost polyisobutylene adhesive systems
• Alternative suppliers for oleic acid and povidone
• Improved coating yields
• Reduced solvent use
• Automated pouching and inspection
• Multi-strength manufacturing on a common platform

The principal commercial risk is market compression after multiple generic approvals. A formulation that is only marginally cheaper may not secure durable share.

Improved adhesion and skin tolerability

A differentiated patch could target patients who experience edge lift, premature detachment, erythema, or adhesive residue. Opportunities include:

• Silicone or hybrid silicone-acrylate adhesives
• Lower-trauma adhesive systems
• Reinforced borders
• Breathable backing films
• Reduced-residue adhesives
• Adhesives optimized for older or fragile skin

These changes may support a 505(b)(2) strategy rather than a conventional ANDA if the product differs materially from the reference system.

Heat-resilient systems

The Butrans label warns against external heat because elevated temperature can increase buprenorphine delivery and opioid exposure.[1] A patch with better resistance to heat-induced flux changes could have commercial value, but the claim must be supported by robust pharmacokinetic and safety data.

Potential approaches include:

• Lower-permeability backing films
• Thermally stable adhesive matrices
• Reduced enhancer volatility
• Drug-binding excipients
• Temperature-responsive release control
• Improved pouch and storage protection

This is a technically attractive but clinically demanding opportunity. The product must demonstrate reduced thermal sensitivity without impairing normal skin delivery.

Abuse-deterrent and diversion-resistant designs

Buprenorphine is a controlled substance. A patch can be evaluated for resistance to extraction, cutting, solvent exposure, and drug recovery. Excipient strategies may include stronger matrix binding, crosslinked polymers, or designs that reduce rapid drug extraction.

A product does not automatically receive abuse-deterrent labeling merely because it is difficult to manipulate. FDA labeling and abuse-deterrence claims require supporting evidence under the relevant regulatory pathway.

Regional and specialty-market products

Commercial opportunities exist outside the U.S. where transdermal buprenorphine is used for chronic pain and, in some markets, different strengths or prescribing practices apply. Regional products can compete through:

• Lower-cost manufacturing
• Localized patch sizes
• Different packaging configurations
• Heat and humidity stability
• Hospital and institutional supply
• Private-label licensing

Geographic freedom-to-operate must be assessed separately because patent expiration, supplementary protection, regulatory approval, and enforcement differ by country.

How does Butrans compare with other transdermal opioid products?

Product	Active ingredient	Delivery format	Excipient opportunity
Butrans	Buprenorphine	Seven-day adhesive patch	Adhesion, enhancer control, heat stability, abuse resistance
Duragesic and generic fentanyl patches	Fentanyl	Multiday transdermal system	Matrix or reservoir design, adhesion, dose dumping control
Lidoderm	Lidocaine	Local anesthetic patch	Local delivery, low systemic exposure, skin tolerability
Buprenorphine weekly patches in other markets	Buprenorphine	Transdermal patch	Strength differentiation, regional formulations, manufacturing scale

Butrans has a favorable potency-to-dose relationship. That reduces the amount of drug required in the patch and can simplify matrix design compared with higher-dose opioid systems. Its risks are tied to opioid safety, heat exposure, adhesion failure, and controlled-substance diversion.

How strong is the Butrans patent estate?

The patent estate is strongest where claims combine the active ingredient with a defined transdermal architecture or excipient system. Broad claims to buprenorphine alone are unlikely to provide meaningful protection because the molecule predates Butrans.

Patent strength should be scored across five factors:

Factor	Assessment
Composition scope	Stronger when claims cover specific enhancer-polymer relationships
Design-around potential	High if competitors can substitute adhesive or enhancer classes
Manufacturing dependence	Stronger when performance requires proprietary coating controls
Orange Book relevance	Stronger when listed patents cover the approved product
Litigation leverage	Higher when multiple patents cover different technical features

The most defensible commercial position combines listed formulation patents, manufacturing know-how, validated adhesion specifications, and regulatory data that are difficult to reproduce economically.

What manufacturing and IP barriers affect commercial entry?

Manufacturing a Butrans-type patch requires precise coating, drying, slitting, lamination, pouching, and inspection. Key process risks include:

• Nonuniform drug distribution
• Coating-weight variation
• Residual solvent
• Adhesive voids
• Edge defects
• Liner separation
• Patch curling
• Crystallization during storage
• Poor pouch seal integrity

The commercial opportunity for excipient suppliers is broader than supplying commodity ingredients. Suppliers can offer qualified adhesive systems, enhancer packages, process-development support, analytical methods, and regulatory documentation. A supplier with a validated transdermal platform can become embedded in multiple generic or 505(b)(2) products.

What is the revenue exposure from Butrans generic competition?

Butrans revenue is exposed to generic erosion because the product uses a conventional small-molecule active and a non-complex transdermal dosage form. The main commercial variables are:

• Number of approved generic manufacturers
• Number of available strengths
• Payer substitution
• Wholesale acquisition price reductions
• Prescriber loyalty
• Patient tolerance of alternative adhesives
• Distributor and pharmacy inventory policies

A differentiated branded patch can preserve share if it demonstrates better adhesion, lower skin irritation, fewer replacement events, or superior heat stability. A generic without those advantages will usually compete on price and formulary access.

Key Takeaways

• Butrans is a seven-day buprenorphine drug-in-adhesive patch.
• Its excipient strategy depends on the interaction among oleic acid, levulinic acid, povidone, polyisobutylene, the backing film, and the release liner.
• The main technical risks are adhesion failure, skin irritation, drug crystallization, dose variability, and heat-related delivery changes.
• Generic entry is more likely to be limited by transdermal performance and regulatory evidence than by the active ingredient.
• The strongest commercial opportunities are improved adhesion, reduced skin irritation, thermal stability, extraction resistance, and lower-cost generic manufacture.
• Excipient patents can remain commercially relevant when they cover a specific enhancer-polymer system or an essential performance characteristic.
• Butrans patent and Orange Book status must be evaluated using current FDA and USPTO records before investment, licensing, or litigation decisions.

FAQs

Can a different adhesive be used in a generic Butrans patch?

Yes. A generic sponsor may use a different adhesive if the product satisfies FDA equivalence requirements and does not infringe enforceable patent claims. The alternative adhesive must support comparable release, adhesion, skin tolerability, and pharmacokinetic performance.

Which excipient is most important for buprenorphine skin delivery?

Oleic acid is a key permeation-enhancement component, but delivery depends on the complete matrix. Adhesive polymer, drug solubility, acid modifier, coating weight, backing film, and skin-contact conditions all affect flux.

Is Butrans a reservoir patch or a matrix patch?

Butrans is generally described as a drug-in-adhesive matrix system. Buprenorphine is incorporated into the adhesive matrix rather than held in a separate liquid reservoir.

Can a transdermal buprenorphine product qualify for a 505(b)(2) application?

Yes, a materially different product may use the 505(b)(2) pathway if it relies in part on FDA findings for an approved product while requiring new information to support the change. The pathway depends on the nature of the formulation, delivery system, indication, and proposed labeling.

Are excipient suppliers potential licensing partners for buprenorphine patches?

Yes. Suppliers with qualified pressure-sensitive adhesives, permeation-enhancer systems, transdermal manufacturing support, and regulatory documentation can license platform technology or enter supply agreements with generic and 505(b)(2) developers.

References

1. U.S. Food and Drug Administration. (2023). Butrans (buprenorphine) transdermal system prescribing information.
2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
3. United States Patent and Trademark Office. (2024). Patent Center and Patent Public Search.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format.
5. U.S. Food and Drug Administration. (2019). Assessment of adhesion performance of transdermal and topical delivery systems for ANDAs: Guidance for industry.